Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MXCT is 91.71M, and currently, short sellers hold a 4.02% ratio of that float. The average trading volume of MXCT on June 19, 2024 was 502.45K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
MXCT) stock’s latest price update
The stock of MaxCyte Inc (NASDAQ: MXCT) has decreased by -5.97 when compared to last closing price of 4.69.Despite this, the company has seen a loss of -5.77% in its stock price over the last five trading days. zacks.com reported 2024-06-13 that The average of price targets set by Wall Street analysts indicates a potential upside of 85% in MaxCyte (MXCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
MXCT’s Market Performance
MaxCyte Inc (MXCT) has seen a -5.77% fall in stock performance for the week, with a -5.57% decline in the past month and a -1.12% plunge in the past quarter. The volatility ratio for the week is 6.83%, and the volatility levels for the past 30 days are at 6.25% for MXCT. The simple moving average for the past 20 days is -6.22% for MXCT’s stock, with a 4.85% simple moving average for the past 200 days.
Analysts’ Opinion of MXCT
Many brokerage firms have already submitted their reports for MXCT stocks, with Craig Hallum repeating the rating for MXCT by listing it as a “Buy.” The predicted price for MXCT in the upcoming period, according to Craig Hallum is $7 based on the research report published on November 29, 2023 of the previous year 2023.
MXCT Trading at 1.51% from the 50-Day Moving Average
After a stumble in the market that brought MXCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.47% of loss for the given period.
Volatility was left at 6.25%, however, over the last 30 days, the volatility rate increased by 6.83%, as shares sank -7.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.52% upper at present.
During the last 5 trading sessions, MXCT fell by -5.77%, which changed the moving average for the period of 200-days by +20.49% in comparison to the 20-day moving average, which settled at $4.69. In addition, MaxCyte Inc saw -6.17% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MXCT starting from Masoud Maher, who purchase 70,443 shares at the price of $4.90 back on Jun 10 ’24. After this action, Masoud Maher now owns 100,000 shares of MaxCyte Inc, valued at $345,241 using the latest closing price.
Masoud Maher, the President and CEO of MaxCyte Inc, purchase 29,557 shares at $4.87 during a trade that took place back on Jun 07 ’24, which means that Masoud Maher is holding 29,557 shares at $143,824 based on the most recent closing price.
Stock Fundamentals for MXCT
Current profitability levels for the company are sitting at:
- -1.07 for the present operating margin
- 0.83 for the gross margin
The net margin for MaxCyte Inc stands at -0.83. The total capital return value is set at -0.19. Equity return is now at value -15.42, with -13.56 for asset returns.
Based on MaxCyte Inc (MXCT), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -1.5. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is -20.62.
Currently, EBITDA for the company is -44.04 million with net debt to EBITDA at 0.08. When we switch over and look at the enterprise to sales, we see a ratio of 10.38. The receivables turnover for the company is 7.35for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.26.
Conclusion
To put it simply, MaxCyte Inc (MXCT) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
